Real-world treatment costs of first-line treatment for metastatic colorectal cancer: a survey of the JCOG colorectal cancer study group.

Atsuo TakashimaMegumi IshiguroKeita SasakiRyunosuke MachidaFumio NagashimaJun ImaizumiTetsuya HamaguchiYoshiyuki YamamotoToshiki MasuishiMasako AsayamaHideki UenoKatsunori ShinozakiToshihiro KudoNozomu MachidaHiroshi MatsuokaHideyuki IshidaToshifumi YamaguchiHitoshi NogamiTakeshi YamadaNaoki TakegawaYosuke KitoYuko TonoikeRyoichi SawadaShunsuke TsukamotoYukihide Kanemitsunull null

Published in: Japanese journal of clinical oncology (2024)

About 16% of mCRC patients received first-line treatment with regimens costing >500 000JPY/month, and molecular targeted drugs being the main drivers of cost.

Keyphrases

metastatic colorectal cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
cancer therapy
combination therapy
study protocol